A preclinical investigation has demonstrated that ginsenoside CK, a bioactive metabolite derived from ginseng, significantly attenuates the progression of nonalcoholic fatty liver disease in rodent and cell models by activating the peroxisome proliferator-activated receptor gamma and carnitine palmitoyltransferase 1A signaling pathway. Published in Biological Procedures Online by an interdisciplinary team from Kunming Medical University and affiliated research institutions, the study combined comprehensive transcriptomic sequencing with rigorous in vivo animal experimentation and in vitro molecular assays to dissect the therapeutic efficacy and targeted biochemical mechanisms of this natural compound. The researchers observed that administering ginsenoside CK to male Sprague-Dawley rats fed a high-fat diet substantially alleviated hepatic steatosis, decreased excessive body weight and organ indices, mitigated hepatocellular damage, and restored systemic insulin sensitivity. Concurrently, parallel experiments using free fatty acid-stimulated human hepatoma Huh7 cells revealed that the compound marked reductions in intracellular lipid droplet accumulation while suppressing oxidative stress and preventing mitochondrial membrane depolarization, confirming a multi-tiered hepatoprotective effect across biological systems.
Nonalcoholic fatty liver disease represents the most prevalent chronic liver disorder across the globe and serves as a major driver in the development of hepatocellular carcinoma, yet clinical pharmacotherapies capable of halting its pathogenic progression remain exceedingly scarce. Pathophysiologically characterized by hepatic steatosis and the abnormal accumulation of triglycerides within liver tissue in the absence of significant alcohol intake, the condition is intimately tied to obesity, dyslipidemia, hyperglycemia, systemic hypertension, and metabolic syndrome. Epidemiological data highlighted in the study indicate that NAFLD prevalence has reached approximately thirty percent in Western populations and roughly twenty percent in China, with diagnostic frequencies continuing an upward trajectory worldwide. Over recent years, clinical understanding of NAFLD progression has evolved from the traditional two-hit hypothesis toward a more intricate multiple-hit paradigm, underscoring multifaceted disturbances in lipid uptake, de novo lipogenesis, mitochondrial bioenergetics, and inflammatory cascades. Because existing management relies heavily on lifestyle adjustments and the symptomatic treatment of metabolic comorbidities, identifying novel and well-tolerated therapeutic candidates derived from traditional medicinal plants has emerged as a promising avenue of translational research.
Prior investigations had demonstrated that this secondary metabolite possesses hepatoprotective attributes, counteracting oxidative injury in drug-induced liver toxicity models by reinforcing endogenous antioxidant defense systems and attenuating toxic lipid peroxidation. Furthermore, earlier animal models of obesity and diabetes revealed that ginsenoside CK can mitigate hepatic lipid deposition through modulation of lipid-handling genes and the stimulation of fatty acid beta-oxidation via 5 prime adenosine monophosphate-activated protein kinase signaling. Despite these preliminary observations regarding general liver protection, the precise molecular targets and regulatory networks through which ginsenoside CK intervenes in diet-induced NAFLD pathology had remained incompletely understood. To resolve this empirical ambiguity, the authors structured a multi-tiered investigation combining dietary modeling in Sprague-Dawley rats, free fatty acid loading in cultured hepatocytes, unbiased RNA sequencing, and functional pathway inhibition experiments to systematically determine whether specific transcriptional axes dictate the compound’s therapeutic actions.
The animal protocol was reviewed and approved by the Ethics Committee of Kunming Medical University under approval number Kmmu20241849, strictly complying with the Guide for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats were acclimatized under a standard twelve-hour light and dark cycle before being assigned into experimental groups via a random number table. To establish hepatic steatosis, animals were maintained on a sixty-kilocalorie percent high-fat diet formulated from standard chow supplemented with ten percent lard, ten percent sucrose, one percent cholesterol, and zero point five percent sodium cholate for six weeks, while control animals consumed standard rodent chow. From week seven through week twelve, interventions were administered via once-daily oral gavage for an additional six weeks, comparing high-fat diet model rats receiving normal saline vehicle at ten milliliters per kilogram per day, animals receiving ginsenoside CK at ten milligrams per kilogram per day, and a positive control group receiving atorvastatin at ten milligrams per kilogram per day. The study adopted a single-blind architecture where tissue harvesters, biochemical assay technicians measuring liver triglyceride endpoints, and data analysts were blinded to group allocations, and an a priori sample size calculation using a two-sided t-test with eighty percent statistical power and an alpha of zero point zero five confirmed that a minimum of six animals per arm was required.
Macroscopic and histological assessments at the twelve-week terminal point revealed pronounced morphological transformations between experimental cohorts. Livers excised from untreated high-fat diet model rats presented diffuse enlargement, a characteristic earth-yellow discoloration, and pervasive pale-yellow lipid droplet accumulation, whereas daily oral administration of ginsenoside CK restored normal gross hepatic coloration, organ architecture, and tissue texture. Hematoxylin and eosin staining alongside quantitative Oil Red O staining demonstrated that ginsenoside CK significantly mitigated hepatocyte ballooning degeneration, parenchymal inflammatory cell infiltration, and intrahepatic neutral lipid deposition. These tissue-level improvements occurred in parallel with marked reductions in terminal body weight, fat index, and liver index in the treated rats, notably taking place without any significant alterations in mean daily food intake across the groups. Furthermore, spectrophotometric serum analyses confirmed that ginsenoside CK substantially diminished circulating levels of liver injury biomarkers, including alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase, while immunofluorescence imaging of liver slices confirmed pronounced suppression of reactive oxygen species generation as well as diminished nuclear factor kappa B and c-Jun N-terminal kinase pathway activation.
Systemic biochemical profiling revealed that ginsenoside CK administration profoundly restructured circulating lipid profiles and corrected peripheral metabolic dysfunction in the diseased rats. High-fat feeding produced dramatic elevations in circulating total cholesterol, serum triglycerides, low-density lipoprotein cholesterol, and non-esterified free fatty acids, accompanied by a marked decrease in cardioprotective high-density lipoprotein cholesterol. Daily treatment with ginsenoside CK successfully reversed these pathological shifts, driving down serum triglycerides, total cholesterol, low-density lipoprotein cholesterol, and non-esterified fatty acids while elevating high-density lipoprotein cholesterol concentrations. Parallel metabolic assessments demonstrated that the compound effectively lowered fasting blood glucose concentrations and circulating insulin titers, thereby yielding a profound reduction in the homeostatic model assessment of insulin resistance index. These systemic endocrine and lipid improvements closely mirrored the protective actions documented in the positive control cohort treated with ten milligrams per kilogram of atorvastatin, demonstrating that ginsenoside CK exerts substantial multi-parametric regulatory control over both circulating lipid turnover and systemic glucose-insulin homeostasis under sustained dietary fat excess.
To interrogate cellular mechanisms independently of systemic neuroendocrine inputs, the authors cultured human Huh7 hepatocytes in Dulbecco’s modified Eagle medium supplemented with ten percent fetal bovine serum and exposed them to a one-millimolar free fatty acid cocktail comprising palmitic acid and oleic acid at a one-to-two ratio for forty-eight hours. Exposing Huh7 cells to this lipid overload triggered massive intracellular lipid droplet accumulation, measurable surges in cellular triglycerides, total cholesterol, and non-esterified fatty acids, and a precipitous decline in mitochondrial membrane potential detected via JC-1 probe fluorescence. Co-treatment with ginsenoside CK at a concentration of ten micromoles per milliliter reversed these pathological phenotypes, drastically clearing intracellular neutral lipids on Oil Red O staining, quenching 2 prime,7 prime-dichlorodihydrofluorescein diacetate-detected reactive oxygen species, and restoring mitochondrial transmembrane polarity. Quantitative real-time polymerase chain reaction and Western blot analyses confirmed that ginsenoside CK significantly downregulated transcriptional and protein expression of major de novo lipogenic drivers, specifically acetyl-CoA carboxylase 1, fatty acid synthase, and sterol regulatory element-binding protein 1c, while concurrently boosting the expression of mitochondrial fatty acid beta-oxidation enzymes carnitine palmitoyltransferase 1 and carnitine palmitoyltransferase 2.
To uncover the central transcriptional networks driving these metabolic adaptations, the investigators conducted high-throughput RNA sequencing on nine Huh7 cell culture libraries using the Edge R bioinformatic package with thresholds of fold change greater than or equal to one point five and p-values below zero point zero five. Transcriptomic comparisons revealed that free fatty acid exposure upregulated one thousand three hundred and fifty genes and downregulated four hundred and thirty-five genes relative to normal controls, whereas ginsenoside CK treatment modulated one thousand two hundred and sixty-seven upregulated and two hundred and ninety-one downregulated transcripts. Direct contrasting of the ginsenoside CK group against untreated fatty model cells uncovered twenty-nine significantly upregulated and ninety significantly downregulated genes, with Venn diagram intersections isolating twenty-three core differentially expressed genes, including carnitine palmitoyltransferase 1A and transgelin. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses indicated that these core targets mapped predominantly into fatty acid biosynthesis, glucose metabolism, long-chain fatty acid transport, and peroxisome proliferator-activated receptor signaling, firmly establishing peroxisome proliferator-activated receptor gamma and its downstream effector carnitine palmitoyltransferase 1A as prime candidates coordinating the drug’s therapeutic actions.
Target validation experiments confirmed that both mRNA and protein levels of peroxisome proliferator-activated receptor gamma and carnitine palmitoyltransferase 1A dropped precipitously in steatotic cell models but experienced robust transcriptional reactivation following ginsenoside CK exposure. To verify functional causality, the team transfected Huh7 cells with specific small interfering RNAs targeting carnitine palmitoyltransferase 1A or applied pharmacological peroxisome proliferator-activated receptor inhibitors at ten micromoles per milliliter. Inhibiting either target abolished the lipid-clearing efficacy of ginsenoside CK, causing rebound surges in intracellular triglycerides, cholesterol, non-esterified fatty acids, and reactive oxygen species, alongside renewed suppression of mitochondrial membrane potentials. Silencing these regulators also re-elevated acetyl-CoA carboxylase 1, fatty acid synthase, and sterol regulatory element-binding protein 1c protein levels while blunting carnitine palmitoyltransferase 2 expression. Crucially, enforcing plasmid-driven carnitine palmitoyltransferase 1A overexpression in cells subjected to peroxisome proliferator-activated receptor gamma inhibition fully rescued the hepatoprotective and anti-steatotic actions of ginsenoside CK, confirming that carnitine palmitoyltransferase 1A operates as an indispensable downstream effector within this transcriptional cascade.
The critical dependence of ginsenoside CK on this regulatory pathway was corroborated through subsequent in vivo targeted inhibition experiments in the high-fat diet-fed rat cohort. When experimental animals receiving ginsenoside CK were administered pathway inhibitors against peroxisome proliferator-activated receptor gamma or carnitine palmitoyltransferase 1A, the compound’s therapeutic benefits were substantially dismantled. Animals subjected to pathway blockade displayed significant re-elevations in gross body weight, hepatic index, and fat index, alongside enlarged, pale liver tissues laden with macroscopic lipid accumulations. Histological analysis via hematoxylin and eosin staining demonstrated the re-emergence of severe hepatocyte ballooning degenerations and lobular inflammatory foci, while serum concentrations of alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase rose back toward disease baseline levels. Furthermore, inhibitor treatment reversed the compound’s suppression of hepatic c-Jun N-terminal kinase and nuclear factor kappa B activation, drove up circulating triglycerides, cholesterol, and low-density lipoprotein levels, depressed high-density lipoprotein cholesterol, and blunted glycemic control, definitively demonstrating that intact peroxisome proliferator-activated receptor gamma and carnitine palmitoyltransferase 1A signaling is essential for ginsenoside CK to exert hepatoprotection in living organisms.
In contextualizing their findings alongside known clinical pharmacology, the researchers highlighted that the protective efficacy of ginsenoside CK closely paralleled the therapeutic profile of atorvastatin, a canonical lipid-lowering agent recognized for anti-inflammatory, antioxidant, and metabolic activities. Mechanistically, while atorvastatin is classical categorized as an agonist of peroxisome proliferator-activated receptor alpha, accumulating biomedical evidence indicates functional crosstalk with peroxisome proliferator-activated receptor gamma and carnitine palmitoyltransferase 1A, either through direct ligand-receptor modulation or indirectly via the energy-sensing adenosine monophosphate-activated protein kinase signaling cascade. The authors noted that natural bioactive molecules like ginsenoside CK frequently govern multi-modal regulatory networks, noting that published studies have linked compound K to anti-adipogenic cascades in 3T3-L1 preadipocytes via adenosine monophosphate-activated protein kinase activation and mitogen-activated protein kinase suppression, hepatic lipid clearance via liver kinase B1 signaling, and beneficial reshaping of gut microbiota through enrichment of Akkermansia muciniphila and shifts in the Bacteroidetes-to-Firmicutes ratio.
Despite these encouraging preclinical outcomes, the study authors explicitly articulated several methodological constraints that temper immediate clinical translation. The experimental protocol relied exclusively on an acute twelve-week rodent feeding regimen with a six-week intervention window, leaving the long-term safety profile, chronic tolerability, and delayed toxicity characteristics of ginsenoside CK unassessed over extended lifespans. Additionally, the experimental design utilized a single fixed dosage of ten milligrams per kilogram per day in vivo and ten micromoles per milliliter in vitro, precluding the establishment of a formal dose-response curve or the identification of a minimum effective dose and maximum tolerated threshold.
Subject of Research: Preclinical investigation of ginsenoside CK mechanisms against nonalcoholic fatty liver disease
Article Title: Activation of PPARγ and CPT1A Mediates the Hepatoprotective Effect of Ginsenoside CK against NAFLD in Rats
Article References: Lan, D., Sun, G., Dong, Z., Li, K., Li, S., He, X., Zou, R., Yang, W., Wang, J., & Wu, B. (2026). Activation of PPARγ and CPT1A Mediates the Hepatoprotective Effect of Ginsenoside CK against NAFLD in Rats. Biological Procedures Online, 28(1), Article 30. https://doi.org/10.1186/s12575-026-00340-6
Image Credits: AI Generated
DOI: 10.1186/s12575-026-00340-6
Keywords: Ginsenoside CK, NAFLD, PPARγ, CPT1A, Hepatic Steatosis, Lipid Metabolism, Atorvastatin, Insulin Resistance, Huh7 Cells, Liver Injury, Activation, PPAR
News Source: Gregory Coleman. (November 10, 2026). Ginsenoside CK Protects Rat Livers by Activating PPARγ and CPT1A Pathways. Scienmag.



